AIkido Pharma Announces Update On Its Use Of Artificial Intelligence

NEW YORK, Sept. 18, 2020 /PRNewswire/ -- AIkido Pharma Inc. AIKI today announced that its work with research partner, Cogia BioTech LTD (www.cogia.de), has delivered several key updates on efforts to accelerate the study of PDA (Pancreatic Ductal Adenocarcinoma) treatments. As previously reported, the Company executed a Scientific Research Agreement with The University of Texas Southwestern Medical Center and Cogia to use machine learning to find genetic markers in people that indicate an increased risk of developing pancreatic cancer.

Cogia Biotech, a Big-data, Artificial Intelligence (AI), and Machine Learning (ML) software company committed to using powerful AI engines and algorithms to develop compelling outcomes in drug development, released a comprehensive progress report to AIkido which included:

• The identification of clusters of markers that interact in signaling pathways affecting PDA survival.
• The development of products and tools to provide extensive information on PDA markers to guide personalized medicine.
• The assembly of survival associations of individual markers from ONCOLNC.org into sets that will help identify novel targets in PDA.
• Information about gene and protein function in human PDA patients and human PDA cancer cell lines to help prioritize individual diagnostic markers.

Anthony Hayes, CEO of AIkido stated, "We are extremely pleased with the progress that Cogia has made in this research project, and are enthusiastic about their continued efforts to develop panels of markers that will rapidly identify patients who have initiated early events in pancreatic cancer. Cogia's Diagnostic Assay Application and Prognostic Marker Characterization Application products assemble essential information on antibodies specific to the respective proteins for more than 20,000 antibody reagents and utilizes the unsupervised learning protocols of the Cogia AI/ML engine to identify clusters of similarly expressed genes, and their association with PDA subtypes.  These tools establish the building blocks of what we continue to believe will be an even broader set of usable full-service products and tools for ongoing and more expanded PDA diagnostics, prognostics, and therapeutics.

About AIkido

AIkido was initially formed in 1967 and is a biotechnology company with a diverse portfolio of small-molecule anti-cancer therapeutics.  The Company's platform consists of patented technology from leading universities and researchers and we are currently in the process of developing an innovative therapeutic drug platform through strong partnerships with world renowned educational institutions, including The University of Texas at Austin and Wake Forest University. Our diverse pipeline of therapeutics includes therapies for pancreatic cancer, acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL). In addition, we are constantly seeking to grow our pipeline to treat unmet medical needs in oncology.  The Company is also developing a broad spectrum antiviral platform that may potentially inhibit replication of multiple viruses including Influenza virus, SARS-CoV (coronavirus), MERS-CoV, Ebolavirus and Marburg virus.

Contact:

Investor Relations:     

Hayden IR
Brett Maas, Managing Partner
Phone: (646) 536-7331
Email: brett@haydenir.com
www.haydenir.com

AIkido:          

Phone: 212-745-1373
Email: investorrelations@AIkido.com
www.AIkido.com

SOURCE AIkido Pharma Inc.